Shuttle Pharma files Form 3 for Co-CEO Trasolini

Shuttle Pharmaceuticals Holdings, Inc. filed an initial Form 3 for Co-Chief Executive Officer Ryan Trasolini.

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. filed an initial Form 3 for Co-Chief Executive Officer Ryan Trasolini. The filing reports his status as an officer of the company but does not list any specific share holdings or recent transactions in company securities.

Key Terms

Form 3, beneficial ownership, Co-Chief Executive Officer

3 terms

Form 3 regulatory

"filed an initial Form 3 for Co-Chief Executive Officer Ryan Trasolini"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"initial statement of beneficial ownership and reports no specific share holdings"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Co-Chief Executive Officer financial

"Ryan Trasolini is reported as an officer of Shuttle Pharmaceuticals, holding the title of Co-Chief Executive Officer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Shuttle Pharmaceuticals (SHPH) Form 3 for Ryan Trasolini show?

The Form 3 identifies Ryan Trasolini as Co-Chief Executive Officer of Shuttle Pharmaceuticals. It serves as his initial statement of beneficial ownership and reports no specific share holdings or recent transactions in SHPH securities at this time.

Is the SHPH Form 3 for Ryan Trasolini a buy or sell signal?

The Form 3 is not a buy or sell signal. It is an initial ownership report for an insider, and this filing shows no reported purchases, sales, or other transactions in Shuttle Pharmaceuticals (SHPH) securities by Ryan Trasolini.

Does Ryan Trasolini report any SHPH share ownership on this Form 3?

This Form 3 does not list any specific share holdings for Ryan Trasolini. The transaction summary fields show zero reported transactions and holdings, indicating no detailed ownership positions are disclosed in this particular filing extract.

What is Ryan Trasolini’s role at Shuttle Pharmaceuticals (SHPH)?

Ryan Trasolini is reported as an officer of Shuttle Pharmaceuticals, holding the title of Co-Chief Executive Officer. This status triggers the requirement to file Form 3 as an insider under SEC beneficial ownership reporting rules for company officers.

Why did Shuttle Pharmaceuticals file a Form 3 for Ryan Trasolini?

Form 3 is required when someone becomes an officer, director, or significant owner of a public company. Shuttle Pharmaceuticals filed this Form 3 because Ryan Trasolini serves as Co-Chief Executive Officer, making him a reporting insider for SHPH under SEC rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 07:11 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Trasolini Ryan

(Last) (First) (Middle)

C/O SHUTTLE PHARMACEUTICALS HOLDINGS

401 PROFESSIONAL DRIVE, SUITE 260

(Street)

GAITHERSBURG MARYLAND 20879

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/06/2026

3. Issuer Name and Ticker or Trading Symbol
Shuttle Pharmaceuticals Holdings, Inc. [ SHPH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

No shares of the Issuer are beneficially owned by the Reporting Person.

No securities are beneficially owned.

	/s/ Ryan Trasolini	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)